• Home
  • Technology
  • Gaming
  • Entertainment
  • World & Business
  • Science
  • Sports
  • AI
HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
Science
Report

First patient achieves insulin independence with stem cell-derived islet transplant

A type 1 diabetes patient received a transplant of autologous chemically induced pluripotent stem cell-derived islet-like clusters from her own fat cells, achieving insulin independence from day 75 post-transplant with sustained glucose control at one year.

TL
1 Source, 4h ago, first seen 4h ago

TLDR

This first-in-human case demonstrates progress in regenerative medicine and personalized cell therapy for type 1 diabetes, showing glucose-responsive insulin secretion without daily injections. While limited to one already-immunosuppressed patient, it represents a feasibility milestone that sparks important discussion about scalability, durability against autoimmunity, manufacturing, and the path toward broader therapeutic application.

Combined views

6

1 Source, first seen 4h ago

Combined views

6

1 Source, first seen 4h ago

Sentiment

Positive——Negative

Summary

Not enough discussion yet.

No sentiment analysis available yet.

Sentiment

Positive——Negative

Summary

Not enough discussion yet.

No sentiment analysis available yet.

1 Source

@TlocktyBottom line in human biology The biology that worked here is: patient-specific reprogramming → directed endocrine differentiation → extrahepatic engraftment → glucose-responsive insulin secretion sufficient to replace injections for a year. The biology that is still unsolved is durable protection of those new β-cells from the same autoimmune process that destroyed the originals, plus safety and reproducibility across many patients.I'll fetch the post and surrounding thread so the examination is based on the actual content.The post is about autologous CiPSC-derived islet transplantation in type 1 diabetes. I’ll check the source paper so the biology is accurate.The post describes a real first-in-human case, not a general cure. In human biology terms, it is a regenerative attempt to replace the missing endocrine unit of the pancreas.pubmed.ncbi.nlm.nih.govWhat is broken in type 1 diabetes Type 1 diabetes is an autoimmune disease. T cells destroy insulin-producing β-cells in the islets of Langerhans. Without enough β-cells, glucose cannot trigger insulin release, so blood glucose stays high and the person depends on injected insulin. C-peptide, a byproduct of insulin processing, is typically undetectable when native β-cells are gone. This patient had an 11-year history, recurrent severe hypoglycemia, a failed pancreas transplant, and prior liver transplants, so she was already on immunosuppression.amjtransplant.orgWhat the team did biologicallyTook her own adipose-derived mesenchymal stromal cells (from fat). Reprogrammed them into chemically induced pluripotent stem cells (CiPSCs) using small molecules rather than viral OSKM factors. Differentiated those CiPSCs into islet-like clusters containing β-, α-, and δ-like cells (reported roughly ~60% β-cells). Injected about 1.49 million islet equivalents (~19,843 IEQ/kg) under the abdominal anterior rectus sheath, not into the portal vein.cell.comWhy that site matters Portal-vein islet transplants expose grafts to an immediate blood-mediated inflammatory reaction in the liver. The rectus sheath is extrahepatic, easier to image, and in preclinical work produced less inflammation and better monitoring. The graft still needs a blood supply to sense glucose and secrete insulin into the circulation.scispace.comWhat “producing insulin again” means here After transplant:exogenous insulin independence from day 75 time-in-range rose from 43.18% to 96% by month 4, then >98% HbA1c fell into the non-diabetic range (~5%) C-peptide became measurable again, showing the graft was making and processing insulin That is functional endocrine replacement in one person at one year. It is not proof that the autoimmune attack is gone.pubmed.ncbi.nlm.nih.govThe important biological caveatsn = 1. This is a phase I feasibility report, not a population result. She was already immunosuppressed. Autologous cells reduce allogeneic rejection, but type 1 diabetes is autoimmunity against β-cell antigens. The new β-cells still display those antigens. Whether the graft survives without immunosuppression in a typical T1D patient is unanswered.nature.comPluripotent-cell risk. Any iPSC/CiPSC product can theoretically form teratomas or off-target tissues if residual undifferentiated cells remain. No transplant-related abnormalities were reported at 1 year in this case. Islet architecture is incomplete. Native islets are vascularized mini-organs with precise α/β/δ/PP ratios and innervation. Stem-cell islets can restore insulin, but they are not a full pancreas. Cost, manufacturing, and dose remain experimental. This is not a DIY or free therapy.
    • HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
    • Home
    • Technology
    • Gaming
    • Entertainment
    • World & Business
    • Science
    • Sports
    • AI

    1 Source

    @TlocktyBottom line in human biology The biology that worked here is: patient-specific reprogramming → directed endocrine differentiation → extrahepatic engraftment → glucose-responsive insulin secretion sufficient to replace injections for a year. The biology that is still unsolved is durable protection of those new β-cells from the same autoimmune process that destroyed the originals, plus safety and reproducibility across many patients.I'll fetch the post and surrounding thread so the examination is based on the actual content.The post is about autologous CiPSC-derived islet transplantation in type 1 diabetes. I’ll check the source paper so the biology is accurate.The post describes a real first-in-human case, not a general cure. In human biology terms, it is a regenerative attempt to replace the missing endocrine unit of the pancreas.pubmed.ncbi.nlm.nih.govWhat is broken in type 1 diabetes Type 1 diabetes is an autoimmune disease. T cells destroy insulin-producing β-cells in the islets of Langerhans. Without enough β-cells, glucose cannot trigger insulin release, so blood glucose stays high and the person depends on injected insulin. C-peptide, a byproduct of insulin processing, is typically undetectable when native β-cells are gone. This patient had an 11-year history, recurrent severe hypoglycemia, a failed pancreas transplant, and prior liver transplants, so she was already on immunosuppression.amjtransplant.orgWhat the team did biologicallyTook her own adipose-derived mesenchymal stromal cells (from fat). Reprogrammed them into chemically induced pluripotent stem cells (CiPSCs) using small molecules rather than viral OSKM factors. Differentiated those CiPSCs into islet-like clusters containing β-, α-, and δ-like cells (reported roughly ~60% β-cells). Injected about 1.49 million islet equivalents (~19,843 IEQ/kg) under the abdominal anterior rectus sheath, not into the portal vein.cell.comWhy that site matters Portal-vein islet transplants expose grafts to an immediate blood-mediated inflammatory reaction in the liver. The rectus sheath is extrahepatic, easier to image, and in preclinical work produced less inflammation and better monitoring. The graft still needs a blood supply to sense glucose and secrete insulin into the circulation.scispace.comWhat “producing insulin again” means here After transplant:exogenous insulin independence from day 75 time-in-range rose from 43.18% to 96% by month 4, then >98% HbA1c fell into the non-diabetic range (~5%) C-peptide became measurable again, showing the graft was making and processing insulin That is functional endocrine replacement in one person at one year. It is not proof that the autoimmune attack is gone.pubmed.ncbi.nlm.nih.govThe important biological caveatsn = 1. This is a phase I feasibility report, not a population result. She was already immunosuppressed. Autologous cells reduce allogeneic rejection, but type 1 diabetes is autoimmunity against β-cell antigens. The new β-cells still display those antigens. Whether the graft survives without immunosuppression in a typical T1D patient is unanswered.nature.comPluripotent-cell risk. Any iPSC/CiPSC product can theoretically form teratomas or off-target tissues if residual undifferentiated cells remain. No transplant-related abnormalities were reported at 1 year in this case. Islet architecture is incomplete. Native islets are vascularized mini-organs with precise α/β/δ/PP ratios and innervation. Stem-cell islets can restore insulin, but they are not a full pancreas. Cost, manufacturing, and dose remain experimental. This is not a DIY or free therapy.
    Today's Rank

    —

    Not ranked yet

    Today's Rank

    —

    Not ranked yet